Role of deferiprone in chelation therapy for transfusional iron overload.
about
Chelation in metal intoxicationDeferasirox for managing iron overload in people with myelodysplastic syndromeDeferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing transfusional iron overload in people with sickle cell diseaseDeferasirox for managing iron overload in people with myelodysplastic syndromeDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing iron overload in patients with myelodysplastic syndromeDeferasirox for managing transfusional iron overload in people with sickle cell diseaseReducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectivesGuidelines on haemovigilance of post-transfusional iron overloadOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.Design of iron chelators with therapeutic application.How I treat Diamond-Blackfan anemia.Clinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.Population pharmacokinetics of deferiprone in healthy subjects.Polymeric nanocarriers for the treatment of systemic iron overload.Purging iron from the heart.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Assessment of thyroid function in children aged 1-13 years with Beta-thalassemia major.Iron overload and chelation.A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.Therapeutic potential of iron chelators in diseases associated with iron mismanagement.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspectiveGlobal epidemiology of haemoglobin disorders and derived service indicators.Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspectiveThyroid function in major thalassemia patients: Is it related to height and chelation therapy?Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations.Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.The treatment of secondary hemochromatosis.Malaria and iron: history and review.Overview of iron chelation therapy with desferrioxamine and deferiprone.Milestones in the history of hemoglobin research (in memory of professor Titus H.J. Huisman).Review of therapeutic options and the management of patients with myelodysplastic syndromes.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.
P2860
Q22305611-6328AE0C-AC7B-4B2F-A7A7-D7B32BABB72CQ24193067-B849F0AD-F10A-4560-ADBD-542293E7CE23Q24194549-31BD82E8-AF67-421F-B09A-74D56355A196Q24203718-DB574447-D424-456F-854E-D5B38338ACD8Q24236463-A72BA11C-0804-4B47-A884-956BD726EC1EQ24236532-216436D4-FCF9-4F71-9A4B-F6D414CCF0C2Q24241753-CFFD0493-71CC-42CE-87BD-769DA60BA089Q24242437-66DBC6CA-DA11-4DCD-B217-92543B2A5AADQ24242535-2DE817DB-0199-4C8B-8736-7B0C495DEE96Q26740347-0ED44949-72E9-4637-A086-559EBB8F8EC9Q27022721-A894C4E0-63A5-4430-8552-C7BEBC48E5EAQ31037298-75DD55E5-971C-44D3-9D75-E5A108C62FADQ33397094-C92DED45-CDD8-4624-9743-6B25B9030FDFQ33407282-B5EE1A06-0FCC-4B45-9429-73546F04B4EBQ33629906-A7DBE7DA-AC35-4542-B050-DF1A3BC607A0Q34258805-94FAB615-E96D-40F8-8419-47885DFFA0E1Q34310852-3AF15FCE-AF30-4609-B477-70F3A9BD7334Q34351633-52FFEED4-AD17-4869-8FA9-7E090FFBC852Q34635568-FAB27D22-6665-4D7E-9B79-75EBC45A1344Q35673632-ACA16F02-432F-4921-88D5-BF1BF659F9E3Q35775328-AD65ACBD-4027-4A4E-8C1B-47DAAF172D96Q35919222-A64C4A48-C02B-4EF0-A8D9-D909825CD53DQ36244654-205E4A61-5833-4FB0-B4E7-4CB8C7A1421AQ36270045-525F5271-FDFC-463B-AF63-43004B796AFBQ36445833-38B58DC5-EA83-43FC-99A0-1A5B11EEB5C9Q36461028-313C0A61-EADE-450A-9FC3-E0B8C8B848E1Q36568908-FEC7EAB0-36C9-498B-A4EB-9AE2A13961A5Q36645815-D9CFEEF0-7F4C-41DC-95BA-87441B0DA888Q37108897-2BCDE4E9-BA31-4261-8C69-6DA5F2F73B78Q37125399-693244CF-63FF-4472-B1C5-A2DDD4CE7439Q37132320-59441E36-1B0C-4D43-B2AE-446105A6FDCFQ37155782-4D6803A0-CA36-43BE-B22E-BF66ECDF727AQ37372868-F46EE065-DDE3-40DE-9E28-56A7F1136CE6Q37528626-544B094E-5B51-445C-8E8E-176F2ACBA92AQ37591211-664FC0E3-D8D1-411F-97AB-02970EEB58FFQ37599856-AF271C4C-068E-400D-9C5A-FB188C4E5B8AQ37650457-20EDA123-AFCB-44F4-BA11-449110B41F66Q37935768-A26AB196-EA4B-4776-A34D-EBCF32DF4A8CQ38095121-6BC1AA47-E614-4226-837B-5B810CBFBD7CQ38874222-748E1FCA-AEA9-453E-A21B-EACA03BFF6CF
P2860
Role of deferiprone in chelation therapy for transfusional iron overload.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Role of deferiprone in chelation therapy for transfusional iron overload.
@ast
Role of deferiprone in chelation therapy for transfusional iron overload.
@en
type
label
Role of deferiprone in chelation therapy for transfusional iron overload.
@ast
Role of deferiprone in chelation therapy for transfusional iron overload.
@en
prefLabel
Role of deferiprone in chelation therapy for transfusional iron overload.
@ast
Role of deferiprone in chelation therapy for transfusional iron overload.
@en
P2093
P1433
P1476
Role of deferiprone in chelation therapy for transfusional iron overload.
@en
P2093
A Victor Hoffbrand
Alan Cohen
Chaim Hershko
P356
10.1182/BLOOD-2002-06-1867
P407
P577
2003-03-13T00:00:00Z